The provided text is only the standard Item 5.02 header and does not contain the specific details of the event required for classification.

Entry into a Material Definitive Agreement. Merger Agreement On September 17, 2026, Aethlon Medical, Inc., a Nevada corporation (the “ Company ”), Nighthawk Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of the Company (the “ First Merger Sub ”), Nighthawk Second Merger Sub, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Company (the “ Second Merger Sub ” and, together with First Merger Sub, the “ Merger Subs ”), and North Immunology, In…

Regulation FD Disclosure. On September 17, 2026, the Company and North Immunology issued a joint press release announcing the entry into the Merger Agreement. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference, except that the information contained on the websites referenced in the press release is not incorporated herein by reference. Exhibit 99.2 hereto and incorporated herein by reference is the investor presentation that…

Changes in Control of Registrant. To the extent required by this Item, the information included in

CEO — James B. Frakes: The filing discloses amendments to employment agreements regarding severance payment timing upon a change in control, not an actual departure or appointment of an executive.

Results of Operations and Financial Condition. The information provided below in “

Material Modification to Rights of Security Holders. On Jul y 30, 2026, Aethlon Medical, Inc., a Nevada corporation (the “Company”), filed a Certificate of Change (the “Certificate of Change”) pursuant to Section 78.209 of the Nevada Revised Statutes (“NRS”) with the Secretary of State of the State of Nevada authorizing a 1-for-5 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”). The…

Entry into a Material Definitive Agreement On July 6, 2026, Aethlon Medical, Inc., a Nevada corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to sell, issue, and deliver, in a registered public offering (the “Offering”) (i) 263,000 shares (“Shares”) of common stock, par value $0.001 per share (the “Common Stock”), (ii) warrants to purchase 5,633,009 shares of Commo…

Results of Operations and Financial Condition. The information provided below in “

Other Events. On December 23, 2025, Aethlon Medical, Inc., a Nevada corporation (the “Company”), filed a prospectus supplement (the “Prospectus Supplement”) with the Securities and Exchange Commission (the “Commission”) relating to the offer and sale of shares of the Company's common stock, par value $0.001 per share (“Common Stock”), from time to time pursuant to that certain At Market Offering Agreement, dated March 24, 2022, as amended on December 19, 2025 (the “ATM Agreement”), by and bet…

The excerpt is incomplete and does not provide enough information to determine the nature of the event.

Results of Operations and Financial Condition. The information provided below in “

Entry into a Material Definitive Agreement. Amendment to Securities Purchase Agreement On January 22, 2026, Aethlon Medical, Inc. (the “Company”) and an institutional investor (the “Purchaser”) entered into the Amendment to Securities Purchase Agreement (the “SPA Amendment”). The SPA Amendment amends the terms of that certain Securities Purchase Agreement by and between the Company and the Purchaser dated December 5, 2025 (the “Securities Purchase Agreement”), as previously disclosed on the C…

Material Modifications to Rights of Security Holders. The disclosure set forth under

Entry into a Material Definitive Agreement. PIPE Offering On December 5, 2025, Aethlon Medical, Inc. (the “Company”) and an institutional investor (the “Purchaser”) entered into a securities purchase agreement (the “Securities Purchase Agreement”), pursuant to which the Company agreed to issue to the Purchaser, in a private placement (the “PIPE Offering”), (i) 596,452 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”) (or pre-funded warrants in li…

Results of Operations and Financial Condition. The information provided below in “

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 16, 2025, Aethlon Medical, Inc. (the “Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock was below $1.00 per share for 30 consecutive business days, the Company was not in compliance with the…

Material Modification to Rights of Security Holders. On October 14, 2025, Aethlon Medical, Inc., a Nevada corporation (the “Company”), filed a Certificate of Change (the “Certificate of Change”) pursuant to Section 78.209 of the Nevada Revised Statutes (“NRS”) with the Secretary of State of the State of Nevada authorizing a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”). T…

Entry into a Material Definitive Agreement On September 4, 2025, Aethlon Medical, Inc., a Nevada corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Investors”), pursuant to which the Company agreed to sell, issue, and deliver, in a registered public offering (the “Offering”) (i) 4,047,780 shares (“Shares”) of common stock, par value $0.001 per share (the “Common Stock”), (ii) 5,000,000 warrants to purchase up to 5,…

Results of Operations and Financial Condition. The information provided below in “

Results of Operations and Financial Condition. The information provided below in “

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. Warrant Inducement Agreement On March 16, 2025, Aethlon Medical, Inc. (the “Company”) entered into a inducement offer to exercise existing Class A and Class B Warrants (the “Agreement”) with a certain accredited and institutional holder (the “Holder”) of the Company’s outstanding Class A and Class B Warrants issued on May 17, 2024 (the “Existing Warrants”). Pursuant to the Agreement, the Holder, upon exercise, will receive a new unregistered Common…

Material Modifications to Rights of Security Holders. The disclosure set forth under

Results of Operations and Financial Condition. The information provided below in “